ArticleClinical journal of the American Society of Nephrology : CJASN2022

A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries.

Annika Khine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.